Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $6.29.

A number of equities research analysts recently issued reports on the stock. Piper Sandler reiterated an "overweight" rating and set a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price for the company in a research report on Thursday, May 15th. Leerink Partnrs upgraded shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. HC Wainwright reiterated a "neutral" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. Finally, Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd.

Fulcrum Therapeutics Trading Up 2.0%

NASDAQ FULC opened at $7.25 on Friday. The company has a fifty day simple moving average of $4.80 and a 200 day simple moving average of $4.16. The company has a market cap of $391.35 million, a P/E ratio of -23.39 and a beta of 2.29. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. Equities research analysts forecast that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. MetLife Investment Management LLC raised its holdings in Fulcrum Therapeutics by 145.8% in the 4th quarter. MetLife Investment Management LLC now owns 40,107 shares of the company's stock valued at $189,000 after buying an additional 23,792 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Fulcrum Therapeutics in the 4th quarter valued at approximately $38,000. American Century Companies Inc. raised its holdings in Fulcrum Therapeutics by 5.9% in the 4th quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock valued at $567,000 after buying an additional 6,770 shares during the last quarter. Northern Trust Corp raised its holdings in Fulcrum Therapeutics by 25.1% in the 4th quarter. Northern Trust Corp now owns 710,321 shares of the company's stock valued at $3,339,000 after buying an additional 142,578 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in Fulcrum Therapeutics by 34.4% in the 4th quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock valued at $161,000 after buying an additional 8,761 shares during the last quarter. Institutional investors own 89.83% of the company's stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.